| Abstrakt: |
Summary: Obstructive sleep apnea (OSA) and cardiovascular co‐morbidities have a mutually reinforcing effect, but existing studies have focussed only on the improvement of the associated co‐morbidities by treatment for OSA. To provide fresh guidelines for the treatment of OSA from a co‐morbidity standpoint, we conducted a systematic search of Web of Science, PubMed, EMBASE, and the Cochrane Library for articles published from inception up to 2 May 2023. Fourteen original studies of patients with OSA with cardiovascular co‐morbidities and who received related treatment were included in the analysis. We found that diuretic treatment can reduce the apnea–hypopnea index in patients with OSA and hypertension (−19.41/h, p = 1.0 × 10−5), aldosterone‐angiotensin inhibitors also have a 9.19/h reduction (p = 0.003), while the effect of renal sympathetic denervation is insignificant (−2.32/h, p = 0.19). The short‐term treatment (<4 weeks) did not show an improvement (−2.72/h, p = 0.16), while long‐term treatment (>4 weeks) produced surprising outcomes (−12.78/h, p = 0.002). Patients with milder disease (baseline AHI < 35/h) had insignificant improvements (−1.05/h, p = 0.46), whereas those with more severe disease (baseline AHI > 35/h) could achieve satisfactory outcomes (−14.74/h, p < 0.00001). In addition, it also showed some improvement in the oxygen desaturation index and blood oxygen. Our results support the additional benefit of antihypertensive treatment for OSA symptoms, and the efficacy can be affected by different therapy, treatment duration, and severity levels. It could be useful in developing clinical therapy, educating patients, and exploring interaction mechanisms. The proposal was registered with PROSPERO (CRD42022351206). [ABSTRACT FROM AUTHOR] |
Plný text